文献速递免疫规划职业卫生

第三剂BNT162b2 COVID-19 mRNA疫苗对医护人员抗SARS-CoV-2抗体水平的影响

Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers.
PubMed 文献 · Vaccine · 2022-11-24

本研究在日本一家医院对636名无COVID-19病史或SARS-CoV-2感染血清学证据的医护人员进行纵向队列研究,测量抗SARS-CoV-2刺突蛋白(SP)和核衣壳蛋白(NP)IgG滴度。结果显示第二剂后抗SP IgG滴度缓慢下降,第三剂后出现强劲抗体应答,峰值约为第一和第二剂后的4.1倍,且第三剂后滴度下降速率较第二剂后显著更缓慢。第三剂疫苗诱导显著且持久的抗SP IgG滴度升高,总体安全且耐受良好。

要点

  • 第三剂BNT162b2疫苗后抗SP IgG峰值滴度约为第一和第二剂后的4.1倍。
  • 第三剂后抗SP IgG滴度下降速率较第二剂后显著更缓慢。
  • 第二剂后老年和男性抗体应答较弱,第三剂后应答无显著性别或年龄差异。

核心结论

  • 第三剂BNT162b2疫苗诱导显著且持久的抗SP IgG滴度升高,总体安全且耐受良好。

研究设计与样本

  • 在日本一家医院开展纵向队列研究,纳入636名无COVID-19病史或SARS-CoV-2感染血清学证据的医护人员。
  • 使用自动化学发光酶免疫测定系统测量抗SARS-CoV-2刺突蛋白(SP)和核衣壳蛋白(NP)IgG滴度。

主要发现

  • 所有参与者第二剂BNT162b2疫苗后抗SP IgG滴度缓慢下降,第三剂后观察到强劲抗体应答。
  • 第三剂后抗SP IgG峰值滴度约为第一和第二剂后的4.1倍。
  • 第三剂后抗SP IgG滴度下降速率较第二剂后显著更缓慢。
  • 第二剂后,老年参与者抗体应答弱于年轻参与者,男性弱于女性;第三剂后应答无显著性别或年龄差异。
  • 免疫接种后不良事件一般为轻至中度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Administration of three doses of Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine was completed in Japan in the spring of 2022. This study aimed to evaluate the antibody responses, and kinetics of three doses of vaccine in healthcare workers (HCWs). PATIENTS AND METHODS: We conducted a longitudinal cohort study with HCWs, who had no history of COVID-19 or serologic evidence of SARS-CoV-2 infection, from a single hospital. Immunoglobulin G (IgG) titers of anti-SARS-CoV-2 spike protein (SP) and nucleocapsid protein (NP) titers were measured using an automated chemiluminescent enzyme immunoassay system. RESULTS: A total of 636 HCWs participated in the study. The anti-SP IgG titers decreased slowly after the second dose of the BNT162b2 vaccine in all participants, and robust antibody response was observed after the third dose of the vaccine. The peak anti-SP IgG titer after the third dose was approximately 4.1-fold higher than that after the first and second doses, and the rate of decrease in the anti-SP IgG titer after the third dose was significantly more gradual, than that after the second dose. After the second dose of vaccine, the antibody response was weaker in older participants than in younger participants, and in males than in females respectively, whereas the response to the third dose of vaccine did not differ significantly by sex or age. Adverse events following immunization were generally mild to moderate. CONCLUSION: The third dose of the BNT162b2 vaccine induced a significant and sustained increase in anti-SP IgG titers, and was generally safe and well-tolerated.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tanaka H, Mukai J, Kushibiki K, et al. Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers. Vaccine. 2022. PMID: 36460533. doi:10.1016/j.vaccine.2022.11.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。